MPE has received funding from the following sources in 2023 and 2024:
Industry supporters
- AbbVie
- Amgen
- Alexion
- BeiGene
- Binding Site
- Bristol Myers Squibb
- GlaxoSmithKline
- Janssen
- Novartis
- Oncopeptides
- Pfizer
- Regeneron
- Roche
- Sanofi
- Menarini Stemline
- Takeda
- Sebia
- Prothena
- SkylineDx
- Sandoz
Public supporters
Horizon Europe
Innovative Medicine Initiative (IMI)
- Horizon 2020 CARAMBA
![EU funded by European Union logo](https://www.mpeurope.org/wp-content/uploads/2023/04/EN-Funded-by-the-EU-PANTONE-1024x215.png)
- Horizon Europe ASCERTAIN
This project has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No 754658.
![EU funded by European Union logo](https://www.mpeurope.org/wp-content/uploads/2023/04/EN-Funded-by-the-EU-PANTONE-1024x215.png)
This project has received funding from the European Union’s Horizon Europe research and innovation programme under grant agreement No 101094938.
- IMI HARMONY
- SISAQOL IMI
You can freely download the funding sources reports by clicking on the links below: